- Home
- PYXS vs VERU Comparison
PYXS vs VERU Comparison
Compare PYXS & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYXS
- VERU
- Stock Information
- Founded
- PYXS 2018
- VERU 1971
- Country
- PYXS United States
- VERU United States
- Employees
- PYXS N/A
- VERU N/A
- Industry
- PYXS Biotechnology: Pharmaceutical Preparations
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- PYXS Health Care
- VERU Health Care
- Exchange
- PYXS Nasdaq
- VERU Nasdaq
- Market Cap
- PYXS 75.0M
- VERU 85.5M
- IPO Year
- PYXS 2021
- VERU 1990
- Fundamental
- Price
- PYXS $1.34
- VERU $3.60
- Analyst Decision
- PYXS Buy
- VERU Strong Buy
- Analyst Count
- PYXS 4
- VERU 3
- Target Price
- PYXS $8.67
- VERU $33.33
- AVG Volume (30 Days)
- PYXS 443.9K
- VERU 227.8K
- Earning Date
- PYXS 08-14-2025
- VERU 08-12-2025
- Dividend Yield
- PYXS N/A
- VERU N/A
- EPS Growth
- PYXS N/A
- VERU N/A
- EPS
- PYXS N/A
- VERU N/A
- Revenue
- PYXS $2,820,000.00
- VERU $16,886,419.00
- Revenue This Year
- PYXS N/A
- VERU N/A
- Revenue Next Year
- PYXS N/A
- VERU N/A
- P/E Ratio
- PYXS N/A
- VERU N/A
- Revenue Growth
- PYXS N/A
- VERU 337.24
- 52 Week Low
- PYXS $0.83
- VERU $2.64
- 52 Week High
- PYXS $5.39
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- PYXS 65.01
- VERU 36.46
- Support Level
- PYXS $1.14
- VERU $2.64
- Resistance Level
- PYXS $1.38
- VERU $3.98
- Average True Range (ATR)
- PYXS 0.09
- VERU 0.40
- MACD
- PYXS 0.03
- VERU 0.03
- Stochastic Oscillator
- PYXS 80.43
- VERU 42.48
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.